10x Genomics (TXG) Tops Q3 EPS by 7c

10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.37), $0.07 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $131.1 million versus the consensus estimate of $129.35 million.

GUIDANCE:

10x Genomics sees FY2022 revenue of $500-520 million, versus the consensus of $509.87 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• 10X Genomics (TXG) PT Raised to $42 at Piper Sandler
• Lucid reports Q2 output, names new CFO and five other leaders
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations